iShares 1-3 Year Treasury Bond ETF (SHY) At $83.56 Forms Bottom; CEMPRA (CEMP) Had 2 Analysts Last Week

iShares 1-3 Year Treasury Bond ETF (SHY) formed multiple bottom with $76.88 target or 8.00% below today’s $83.56 share price. iShares 1-3 Year Treasury Bond ETF (SHY) has $11.20B valuation. The ETF increased 0.04% or $0.03 during the last trading session, reaching $83.56. About 3.00M shares traded or 116.02% up from the average. iShares 1-3 Year Treasury Bond ETF (NASDAQ:SHY) has declined 1.18% since March 31, 2017 and is downtrending. It has underperformed by 12.73% the S&P500.

Among 16 analysts covering Cempra (NASDAQ:CEMP), 2 have Buy rating, 2 Sell and 12 Hold. Therefore 13% are positive. Cempra had 41 analyst reports since July 30, 2015 according to SRatingsIntel. The rating was downgraded by Gabelli on Monday, November 7 to “Hold”. The firm has “Buy” rating given on Thursday, July 30 by Needham. The company was maintained on Monday, October 30 by Robert W. Baird. The company was downgraded on Friday, December 30 by TH Capital. Robert W. Baird maintained CEMPRA INC (NASDAQ:CEMP) rating on Friday, September 29. Robert W. Baird has “Sell” rating and $2.0 target. The stock has “Buy” rating by TH Capital on Monday, October 19. The firm has “Hold” rating by Needham given on Sunday, November 13. SunTrust downgraded the shares of CEMP in report on Tuesday, December 20 to “Sell” rating. On Thursday, August 13 the stock rating was initiated by Morgan Stanley with “Equal-Weight”. The stock of CEMPRA INC (NASDAQ:CEMP) earned “Neutral” rating by Roth Capital on Friday, December 30. See CEMPRA INC (NASDAQ:CEMP) latest ratings:

01/11/2017 Broker: Robert W. Baird Rating: Hold New Target: $2.0 Upgrade
30/10/2017 Broker: Robert W. Baird Rating: Sell New Target: $2.0 Maintain
27/10/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $4.0 Maintain

The stock increased 1.09% or $0.025 during the last trading session, reaching $2.325. About 511,621 shares traded or Infinity% up from the average. CEMPRA INC (NASDAQ:CEMP) has 0.00% since March 31, 2017 and is . It has underperformed by 11.55% the S&P500.

Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of infectious diseases in North America. The company has market cap of $. The Company’s lead product candidate is solithromycin, which is in Phase III clinical trials developed in oral capsules, intravenous, and suspension formulations for the treatment of community-acquired bacterial pneumonia in adults and children, as well as for ophthalmic infections and other indications. It currently has negative earnings. The firm is also developing fusidic acid, an antibiotic, which is in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections.

CEMPRA INC (NASDAQ:CEMP) Ratings Chart